Tags

Type your tag names separated by a space and hit enter

Current status of methyl acetimidate as an extracorporeal antisickling agent.
Am J Pediatr Hematol Oncol. 1984 Spring; 6(1):55-8.AJ

Abstract

Methyl acetimidate has been shown to be an effective in vitro antisickling agent with few detrimental effects on the red cell. 51Cr-survival of red cells that had been incubated in vitro with methyl acetimidate was prolonged to near normal levels in sickle cell anemia patients. However, some patients developed an immune response following multiple reinfusions of the acetamidinated cells. Pre-equilibration of erythrocytes with the membrane-impermeable aldehyde, pyridoxal 5'-phosphate, prior to the addition of methyl acetimidate to the reaction mixture, has been shown to prevent agglutination of acetamidinated cells which were resuspended in immune serum. However, the protection was not extensive enough to prevent an immune response in a sickle cell anemia patient who had already been sensitized against acetamidinated cells. It is apparent that further consideration of imidoesters as extracorporeal antisickling agents will require complete protection of membrane amino groups against reaction with the imidoester.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

6711765

Citation

Chao, T L., et al. "Current Status of Methyl Acetimidate as an Extracorporeal Antisickling Agent." The American Journal of Pediatric Hematology/oncology, vol. 6, no. 1, 1984, pp. 55-8.
Chao TL, Berenfeld MR, Gabuzda TG. Current status of methyl acetimidate as an extracorporeal antisickling agent. Am J Pediatr Hematol Oncol. 1984;6(1):55-8.
Chao, T. L., Berenfeld, M. R., & Gabuzda, T. G. (1984). Current status of methyl acetimidate as an extracorporeal antisickling agent. The American Journal of Pediatric Hematology/oncology, 6(1), 55-8.
Chao TL, Berenfeld MR, Gabuzda TG. Current Status of Methyl Acetimidate as an Extracorporeal Antisickling Agent. Am J Pediatr Hematol Oncol. 1984;6(1):55-8. PubMed PMID: 6711765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of methyl acetimidate as an extracorporeal antisickling agent. AU - Chao,T L, AU - Berenfeld,M R, AU - Gabuzda,T G, PY - 1984/1/1/pubmed PY - 1984/1/1/medline PY - 1984/1/1/entrez SP - 55 EP - 8 JF - The American journal of pediatric hematology/oncology JO - Am J Pediatr Hematol Oncol VL - 6 IS - 1 N2 - Methyl acetimidate has been shown to be an effective in vitro antisickling agent with few detrimental effects on the red cell. 51Cr-survival of red cells that had been incubated in vitro with methyl acetimidate was prolonged to near normal levels in sickle cell anemia patients. However, some patients developed an immune response following multiple reinfusions of the acetamidinated cells. Pre-equilibration of erythrocytes with the membrane-impermeable aldehyde, pyridoxal 5'-phosphate, prior to the addition of methyl acetimidate to the reaction mixture, has been shown to prevent agglutination of acetamidinated cells which were resuspended in immune serum. However, the protection was not extensive enough to prevent an immune response in a sickle cell anemia patient who had already been sensitized against acetamidinated cells. It is apparent that further consideration of imidoesters as extracorporeal antisickling agents will require complete protection of membrane amino groups against reaction with the imidoester. SN - 0192-8562 UR - https://www.unboundmedicine.com/medline/citation/6711765/Current_status_of_methyl_acetimidate_as_an_extracorporeal_antisickling_agent_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=6711765.ui DB - PRIME DP - Unbound Medicine ER -